Clinical trial
Prospective Randomised Investigation of the Safety and Efficacy of Micardis® vs…
NCT00274612 · Boehringer Ingelheim, Industry · Completed
Key facts
| NCT number | NCT00274612 |
|---|---|
| Title | Prospective Randomised Investigation of the Safety and Efficacy of Micardis® vs Ramipril Using ABPM |
| Official title | A Prospective Randomised Open- Label Blinded-Endpoint (PROBE) Trial Comparing Telmisartan (MICARDIS®) (40-80-80mg QD) and Ramipril (2.5-5--10mg QD) in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring. PRISMA = Prospective Randomised Investigation of the Safety… |
| Acronym | PRISMA |
| Lead sponsor | Boehringer Ingelheim, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Hypertension |
| Intervention type | Drug |
| Interventions | Telmisartan, Ramipril |
| Enrollment | 801 |
| Start date | Oct 1, 2002 |
| Primary completion | Nov 1, 2003 |
| Completion | Nov 1, 2003 |
| First posted | Jan 11, 2006 |
| Last update posted | Nov 1, 2013 |
| Countries | Austria, France, Germany, Netherlands, South Africa, Spain, Switzerland, United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: